AstraZeneca is scheduled Sunday to present results from a 17,802-patient clinical trial of Crestor, a cholesterol-lowering statin, that could significantly widen the market for such drugs, experts said. Other experts said the findings could spur changes to cholesterol-treatment guidelines, including a wider use of C-reactive protein in screening patients for heart risks.

Related Summaries